Xerostomia: a brief look of the problem


Cite item

Full Text

Abstract

Xerostomia is iatrogenically and non-iatrogenically manifested in patients for a number of reasons and detectable in 12% of the world’s population and its prevalence in the elderly amounts to as much as 25%. Oncologically, xerostomia remains a problem in patients receiving radiotherapy for malignant tumors of the upper respiratory and digestive tracts. The basis for hyposialia prophylaxis is oral hygiene (that is to prevent and treat caries and fungal superinfection). In more complex cases of significant xerostomia, saliva substitutes are used, which give patients instant functional relief.

About the authors

S O Podvyaznikov

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава РФ, Москва

д-р мед. наук, проф. каф. онкологии

References

  1. Guggenheimer J et al. J Am Dent Assos 2003; 13: 61–9.
  2. Altkinson J.C. et al. Dent Clin North AM 2005; 49 (2): 309–26.
  3. Mariette X. Rev Med Intern 2004; 25: 287–93.
  4. Sciubba J.J. et al. Lancet Oncol 2006; 7 (2): 175–83.
  5. Dirix P et al. Cancer 2006; 107 (1): 2525–34.
  6. Gentric-Tilly A et al. Ann Med Intern (Paris) 2002; 153: 378–82.
  7. Novaresh M et al. JADA 2008; 139: 355–405.
  8. Mariette X. Rev Med Intern 2004; 25: 287–93.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies